TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Two phase III trials found that once-daily orforglipron reduced apnea-hypopnea index scores more than placebo over 52 weeks in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity. The drug is already FDA-approved for weight management, but its use for sleep apnea would require separate approval; gastrointestinal events were common in the trials.
Orforglipron, an oral GLP-1 drug, improved measures of sleep-disordered breathing compared with placebo in two 52-week phase III trials involving adults with moderate-to-severe obstructive sleep apnea and overweight or obesity. The results, presented at the American Heart Association meeting and published in JAMA, suggest the medicine could offer a tablet option for sleep apnea if regulators approve it for that use; it is not currently approved to treat sleep apnea.
The ATTAIN-OSA trials measured changes in the apnea-hypopnea index (AHI), which counts breathing interruptions and reductions in breathing during sleep. At week 52, the treatment-regimen analysis found mean AHI reductions of 17.3 events per hour with orforglipron and 5.3 with placebo among participants using positive airway pressure (PAP). Among participants not using PAP, the corresponding reductions were 17.8 and 4.5 events per hour. Both comparisons favored orforglipron, with P<0.001.
The trials enrolled 349 people using PAP and 363 not using it. Participants were adults with moderate-to-severe obstructive sleep apnea and a body mass index of at least 27. They were randomly assigned to once-daily orforglipron at a maximum tolerated dose or placebo. Researchers also reported improvements in sleep apnea-specific hypoxic burden, body weight, high-sensitivity C-reactive protein and blood pressure.
Gastrointestinal events were the most commonly reported adverse events. In the trial without PAP, they occurred in 68% of orforglipron recipients and 37.4% of placebo recipients; in the PAP trial, the rates were 70.6% and 36.6%. The supplied report does not detail the severity or duration of these events. The results were reported by Vaishnavi Kundel, MD, of the Icahn School of Medicine at Mount Sinai.
A Tablet Option for Sleep Apnea
Obstructive sleep apnea can require long-term treatment, and the trial findings add a potential once-daily oral option to a field where PAP devices are a central treatment. A tablet could appeal to some patients who find equipment difficult to use, though the trial results do not establish that orforglipron can replace PAP or other established care.
Michael Grandner, PhD, of the University of Arizona, said existing devices can work well but may be complicated to use, and that use among people treated for sleep apnea is relatively low. He described an oral option as potentially useful, while the evidence presented so far supports a more limited conclusion: the drug improved measured breathing outcomes against placebo over one year. Whether that translates into better long-term health or broader treatment uptake is not yet known.
Orforglipron also showed changes in weight, blood pressure and an inflammatory marker, but these findings should not be read as proof that it reduces cardiovascular events. The report says cardiovascular risk reduction with orforglipron has not been established. The findings may inform future treatment discussions, particularly for patients who also have overweight or obesity, but the trial population and results do not resolve which treatment is best for an individual.
Popular right now
Dyson V15 Detect Cordless Vacuum
Breville Barista Touch Impress Espresso Machine, Noir (BES881NRE)
Vitamix 5200 Blender with 64 oz. Container, Black
As an affiliate, we earn on qualifying purchases.
How Orforglipron Fits Current Care
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken by mouth. It has already received FDA approval for weight management, according to the report; that approval is distinct from approval to treat obstructive sleep apnea. The ATTAIN-OSA studies tested the medicine specifically in people with sleep apnea and overweight or obesity.
The two double-blind, placebo-controlled trials were conducted at 66 sites in the United States and eight other countries or territories. Participants received a maximum tolerated dose equivalent to a 9-, 14.5- or 17.2-mg tablet dose. The report describes the findings as the first oral therapy to show improvement in disordered breathing in these trials, but any claim that it would become the first approved oral sleep apnea treatment depends on regulatory review.
At the meeting, Ildiko Lingvay, MD, MPH, of UT Southwestern Medical Center compared the results with those for tirzepatide, which is already FDA-approved for obstructive sleep apnea. She said tirzepatide appeared to have advantages in the degree of AHI and hypoxic-burden improvement and in safety measures, while noting that orforglipron’s tablet form and once-daily dosing distinguish it from an injectable medicine requiring cold-chain supply.
“The biggest benefit of orforglipron is really the fact that it comes in a tablet form, for once-daily administration, while tirzepatide requires a cold chain supply and injections.”
— Ildiko Lingvay, MD, MPH, of UT Southwestern Medical Center
Approval and Long-Term Outcomes
The trial results do not mean orforglipron is approved for sleep apnea. The source report does not say whether the manufacturer has submitted, or plans to submit, an application for that indication, or when regulators might make a decision. It is also unclear how the drug would perform outside the 52-week study period and whether patients would maintain the observed improvements with longer use.
The findings compare orforglipron with placebo, not directly with PAP, oral appliances or other medicines. The report gives no head-to-head trial results establishing which treatment controls sleep apnea best, and it does not establish that the observed changes lower rates of heart attack, stroke or other cardiovascular events. Adverse-event figures show gastrointestinal events were more frequent with orforglipron, but the supplied material does not provide a full breakdown of event severity, discontinuations or other safety outcomes.
Comparative Trials and Regulatory Review
The next steps for the drug’s potential sleep apnea use depend on whether its maker seeks a separate FDA indication and how regulators assess the trial data. The source material does not provide a submission or decision timeline. In the meantime, the published results offer evidence of improvement against placebo, not a change to current treatment guidance.
The editorial authors called for pragmatic trials comparing or combining orforglipron with PAP, oral appliances, tirzepatide and other care. Such studies could clarify how the oral drug works alongside existing treatments, which patients might benefit most, and whether breathing improvements persist. Until those questions are answered, clinicians and patients will need to interpret the results within the limits of the available evidence and existing approved treatments.
Key Questions
What did the orforglipron trials find?
In two 52-week trials, orforglipron reduced mean apnea-hypopnea index scores more than placebo among adults with moderate-to-severe obstructive sleep apnea and overweight or obesity, whether or not they were using PAP.
Is orforglipron approved to treat sleep apnea?
No sleep apnea approval is reported. The source says orforglipron is FDA-approved for weight management; approval for that use is separate from approval to treat obstructive sleep apnea.
What side effects were reported?
Gastrointestinal events were the most commonly reported adverse events. They occurred in 68% versus 37.4% of participants in the trial without PAP and 70.6% versus 36.6% in the PAP trial, comparing orforglipron with placebo.
Could the pill replace a PAP device?
The trials do not establish that orforglipron can replace PAP. Researchers studied participants both using and not using PAP, but the report says comparisons and combination studies with established treatments are still needed.
How does it compare with tirzepatide?
The report does not describe a direct head-to-head trial. Meeting discussant Ildiko Lingvay said tirzepatide appeared to have advantages in some sleep apnea measures and safety outcomes, while orforglipron is taken as a once-daily tablet.
Source: medpagetoday.com
